Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LAP3 | P28838 | 5/20 | 0.57 |
| ▸ | ANPEP | P15144 | 4/20 | 0.57 |
| ▸ | ALPI | P09923 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.56 |
| ▸ | XIAP | P98170 | 1/20 | 0.56 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.56 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.49 |
| ▸ | ACP3 | P15309 | 1/20 | 0.47 |
| ▸ | PTPRC | P08575 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.46 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9137964 | 0.86 | ALPI (0.51) | LAP3ANPEPALPIPKMPTGS1 | |
| SCHEMBL9140740 | 0.85 | ALPI (0.50) | LAP3ANPEPALPIPKMPTGS1 | |
| SCHEMBL9242132 | 0.84 | LAP3 (0.54) | LAP3ANPEPALPIPKMPTGS1 | |
| SCHEMBL5307576 | 0.83 | ALPI (0.51) | LAP3ANPEPALPIPKMPTGS1 | |
| SCHEMBL4958184 | 0.82 | ALPI (0.58) | LAP3ANPEPALPIPKMPTGS1 | |
| SCHEMBL18025352 | 0.81 | SLC7A5 (0.66) | LAP3ANPEPALPIPKMPTGS1 | |
| SCHEMBL26359430 | 0.81 | ALPI (0.66) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL15679078 | 0.81 | ALPI (0.66) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL2785098 | 0.81 | SLC7A5 (0.70) | LAP3ANPEPALPIPKMPTGS1 | |
| Phenylalanine Methyl Ester SCHEMBL9355493 | 0.81 | LAP3 (0.58) | LAP3ANPEPALPIPKMPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7132392-B1 | Inhibition of cell motility and angiogenesis by inhibitors of Grb2-SH2-domain | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-11-07 | — | — | US | claimed |
| EP-1140980-B1 | PSEUDOPEPTIDE COMPOUNDS HAVING AN INHIBITING ACTIVITY WITH RESPECT TO PATHS ACTIVATED BY PROTEINS WITH ACTIVE TYROSINE KINASE ACTIVITY AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | INST NAT SANTE RECH MED (FR) | 2004-09-29 | — | — | EP | claimed |
| EP-1223959-A2 | INHBITION OF CELL MOTILITY AND ANGIOGENESIS BY INHIBITORS OF THE GRB2 SH2-DOMAIN | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2002-07-24 | — | — | EP | claimed |
| US-6307090-B1 | OXALYL ENDCAPPED; CONTAINING A BIVALENT RADICAL OF PHOSPHOTYROSINE OR A PHOSPHOTYROSINE MIMETIC | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2001-10-23 | — | — | US | claimed |
| WO-2001028577-A2 | INHIBITION OF CELL MOTILITY AND ANGIOGENESIS BY INHIBITORS OF THE GRB2 SH2-DOMAIN | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2001-04-26 | — | — | WO | claimed |
| CN-114127272-B | Engineered imine reductase and methods for reductive amination of ketone and amine compounds | 科德克希思公司 | 2025-05-27 | — | — | CN | disclosed |
| CN-114555795-B | Ketoreductase polypeptides and polynucleotides | 科德克希思公司 | 2025-05-27 | — | — | CN | disclosed |
| CN-114096662-B | Engineered glucose dehydrogenase and method for reductive amination of ketone and amine compounds | 科德克希思公司 | 2025-04-15 | — | — | CN | disclosed |
| CN-113396218-B | Engineered transaminase polypeptides | 科德克希思公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-118871576-A | Engineered monoamine oxidase for preparing stereoisomerically pure fused bicyclic proline compounds | 科德克希思公司 | 2024-10-29 | — | — | CN | disclosed |
| CN-118647711-A | Engineered enone reductase and ketoreductase variant enzymes | 科德克希思公司 | 2024-09-13 | — | — | CN | disclosed |
| CN-118369421-A | Engineered threonine aldolase and amino acid decarboxylase | 科德克希思公司 | 2024-07-19 | — | — | CN | disclosed |
| US-5770620-A | ENZYME INHIBITOR AS IMMUNOMODULATORS | ONTOGEN CORPORATION (US) | 1998-06-23 | — | — | US | disclosed |
| EP-0847443-A1 | CRYSTALLINE ZAP FAMILY PROTEINS | ARIAD PHARMACEUTICALS, INC. (US) | 1998-06-17 | — | — | EP | disclosed |
| US-5753687-A | ACRYLATED ARYLIMIDAZOLE DERIVATIVES | ONTOGEN CORPORATION (US) | 1998-05-19 | — | — | US | disclosed |
| WO-1997039748-A1 | MODULATORS OF MOLECULES WITH PHOSPHOTYROSINE RECOGNITION UNITS | NOVO NORDISK A/S (DK) | 1997-10-30 | — | — | WO | disclosed |
| WO-1997040017-A2 | MODULATORS OF MOLECULES WITH PHOSPHOTYROSINE RECOGNITION UNITS | NOVO NORDISK A/S (DK) | 1997-10-30 | — | — | WO | disclosed |
| WO-1997008300-A1 | CRYSTALLINE ZAP FAMILY PROTEINS | ARIAD PHARMACEUTICALS, INC. (US) | 1997-03-06 | — | — | WO | disclosed |
| US-5475129-A | Phosphonoalkyl phenylalanine compounds suitably protected for use in peptide synthesis | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1995-12-12 | — | — | US | disclosed |
| WO-1993025561-A1 | PHOSPHONOALKYL PHENYLALANINE COMPOUNDS SUITABLY PROTECTED FOR USE IN PEPTIDE SYNTHESIS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1993-12-23 | — | — | WO | disclosed |